Rakesh Kumar Tekade

List of Publications by Year in Descending Order

236 papers	6,373 citations	49 h-index	76 g-index
240 ext. papers	7,543 ext. citations	6.2 avg, IF	6.52 L-index

#	Paper	IF	Citations
236	Toxicogenomics in drug safety assessment **2022**, 73-98		
235	Food–drug interactions and their implications on oral drug bioavailability **2022**, 263-289		
234	Factors influencing drug toxicity **2022**, 27-50		
233	Molecular biology of apoptotic, necrotic, and necroptotic cell death **2022**, 51-72		
232	Toxicokinetic and toxicodynamic considerations in drug research **2022**, 751-776		
231	Toxicological assessment of risk of medical devices **2022**, 651-684		
230	Importance of toxicity testing in drug discovery and research **2022**, 117-144		2
229	Developmental toxicity of nanomaterials used in drug delivery: understanding molecular biomechanics and potential remedial measures **2022**, 685-725		0
228	Environmental and safety aspects of bionanotechnology **2022**, 605-650		
227	Excipient toxicity and safety **2022**, 487-511		
226	Impact of ageing on the pharmacokinetics and pharmacodynamics of the drugs **2022**, 241-261		
225	Toxicity of pharmaceutical azo dyes **2022**, 569-603		1
224	Methods and models for in vitro toxicity **2022**, 145-174		
223	Toxicity and toxicokinetic considerations in product development and drug research **2022**, 401-424		
222	In silico methods for the prediction of drug toxicity **2022**, 357-383		0
221	Principles and concepts in toxicokinetic **2022**, 1-26		
220	Drug–drug interactions and their implications on the pharmacokinetics of the drugs **2022**, 291-322		

219	Nanomaterials assisted chemo-photothermal therapy for combating cancer drug resistance. *Journal of Drug Delivery Science and Technology*, **2022**, 103164	4.5	1
218	Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery.. *Drug Metabolism Reviews*, **2022**, 1-19	7	0
217	Current trends in theranostic nanomedicines. *Journal of Drug Delivery Science and Technology*, **2022**, 71, 103280	4.5	7
216	Engineering immunity via skin-directed drug delivery devices.. *Journal of Controlled Release*, **2022**, 345, 385-404	11.7	8
215	Dendrimers: Properties and Applications in Biomedical Field **2022**, 215-243		1
214	Current Scenario and Future Prospect in the Management of COVID-19. *Current Medicinal Chemistry* , **2021**, 28, 284-307	4.3	13
213	Recent advancements and future submissions of silica core-shell nanoparticles. *International Journal of Pharmaceutics*, **2021**, 609, 121173	6.5	8
212	Reinforced electrospun nanofiber composites for drug delivery applications. *Journal of Biomedical Materials Research - Part A*, **2021**, 109, 2036-2064	5.4	5
211	Nanomedicine in the treatment of diabetic nephropathy. *Future Medicinal Chemistry*, **2021**, 13, 663-686	4.1	3
210	Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis. *Drug Discovery Today*, **2021**, 26, 2315-2328	8.8	7
209	Advancements in practical and scientific bioanalytical approaches to metabolism studies in drug development. *Bioanalysis*, **2021**, 13, 913-930	2.1	3
208	Nanoplatform-Integrated Miniaturized Solid-Phase Extraction Techniques: A Critical Review. *Critical Reviews in Analytical Chemistry*, **2021**, 1-23	5.2	
207	Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 42, 128062	2.9	2
206	Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer. *Materials Science and Engineering C*, **2021**, 126, 112186	8.3	10
205	Cyclo-RGD Truncated Polymeric Nanoconstruct with Dendrimeric Templates for Targeted HDAC4 Gene Silencing in a Diabetic Nephropathy Mouse Model. *Molecular Pharmaceutics*, **2021**, 18, 641-666	5.6	7
204	Artificial intelligence in drug discovery and development. *Drug Discovery Today*, **2021**, 26, 80-93	8.8	107
203	To investigate fit-to-purpose nanocarrier for non-invasive drug delivery to posterior segment of eye. *Journal of Drug Delivery Science and Technology*, **2021**, 61, 102222	4.5	2
202	Glucosamine-conjugated nanoseeds for chemo-magneto hyperthermia therapy of cancer. *Journal of Drug Delivery Science and Technology*, **2021**, 61, 102295	4.5	4

201	Pharmacokinetics and biopharmaceutics: a leader or attendant? **2021**, 17-27		
200	Pharmacokinetics modeling in drug delivery **2021**, 279-334		
199	Chronopharmacokinetics **2021**, 163-194		
198	Software used in ADME computation **2021**, 699-708		
197	Overview of biopharmaceutics and pharmacokinetics **2021**, 1-16		
196	Biopharmaceutical considerations in the pediatric and geriatric formulation development **2021**, 109-144		
195	Nanomedicines accessible in the market for clinical interventions. *Journal of Controlled Release*, **2021**, 330, 372-397	11.7	56
194	Innovation in bioanalytical strategies and drug-drug interaction study approaches in drug discovery. *Bioanalysis*, **2021**, 13, 513-532	2.1	3
193	Engineered nanoplex mediated targeted miRNA delivery to rescue dying podocytes in diabetic nephropathy. *International Journal of Pharmaceutics*, **2021**, 605, 120842	6.5	5
192	Emerging roles and biopharmaceutical applications of milk derived exosomes. *Journal of Drug Delivery Science and Technology*, **2021**, 64, 102577	4.5	0
191	Biosimilars accessible in the market for the treatment of cancer. *Journal of Controlled Release*, **2021** , 336, 112-129	11.7	20
190	Pharmacokinetics aspects of biotechnological products **2021**, 539-565		0
189	Current strategies in targeted anticancer drug delivery systems to brain **2021**, 267-280		
188	Influence of fever on pharmacokinetics of drugs **2021**, 451-463		
187	Laser activatable nanographene colloids for chemo-photothermal combined gene therapy of triple-negative breast cancer.. *Materials Science and Engineering C*, **2021**, 112605	8.3	0
186	Advancements in sterile products and admixtures **2020**, 671-694		
185	Endosomal escape tendency of drug delivery systems to mediate cytosolic delivery of therapeutics **2020**, 227-258		1
184	NanoGold-core dendrimeric seeds for combined chemo-, photothermal-, and photodynamic therapy of cancer. *Journal of Drug Delivery Science and Technology*, **2020**, 58, 101814	4.5	8

183	Green graphene nanoplates for combined photo-chemo-thermal therapy of triple-negative breast cancer. *Nanomedicine*, **2020**, 15, 581-601	5.6	14
182	Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities. *Drug Discovery Today*, **2020**, 25, 862-878	8.8	17
181	Recent advances in regenerative medicine **2020**, 367-412		
180	Achieving sterility in biomedical and pharmaceutical products (part-II): radiation sterilization **2020**, 789-848		
179	Mass spectrometry imaging in lipid and proteomic profiling: an emerging tool for cancer diagnosis **2020**, 259-295		0
178	Gene delivery to tackle diabetic nephropathy **2020**, 515-537		
177	Small interfering RNA-based advanced nanoparticles for the treatment of cancer **2020**, 341-365		
176	Resealed erythrocytes (RBCs) and their biomedical application **2020**, 539-580		
175	Recombinant blood products and therapeutic enzymes: An update **2020**, 447-482		0
174	Pharmacogenomics and pharmacoepigenomics: Impact on therapeutic strategies **2020**, 413-446		
173	Photothermal therapy as emerging combinatorial therapeutic approach **2020**, 297-339		3
172	New advances in insulin products **2020**, 483-514		1
171	Proliposomes: a potential colloidal carrier for drug delivery applications **2020**, 581-608		3
170	Gold nanoparticles: An advanced drug delivery and diagnostic tool **2020**, 609-669		3
169	Current advances in the clinical development of anti-tubercular agents. *Tuberculosis*, **2020**, 125, 101989	2.6	9
168	Coating technologies in pharmaceutical product development **2020**, 665-719		10
167	Polymeric micelles: a ray of hope among new drug delivery systems **2020**, 235-289		8
166	Fundamentals of diffusion and dissolution: dissolution testing of pharmaceuticals **2020**, 1-45		2

165	Dendrimers as novel drug-delivery system and its applications **2020**, 333-392		10
164	Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson's disease. *Drug Discovery Today*, **2020**, 25, 392-405	8.8	6
163	miR-29b attenuates histone deacetylase-4 mediated podocyte dysfunction and renal fibrosis in diabetic nephropathy. *Journal of Diabetes and Metabolic Disorders*, **2020**, 19, 13-27	2.5	12
162	Cancer-targeted chemotherapy: Emerging role of the folate anchored dendrimer as drug delivery nanocarrier **2020**, 151-198		9
161	Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach-A Novel and Potential Antibacterial Formulation. *Pharmaceutics*, **2020**, 12,	6.4	30
160	Exosomes in multidrug-resistant cancer. *Current Opinion in Pharmacology*, **2020**, 54, 109-120	5.1	3
159	Recent advancements in solubilization of hydrophobic drugs **2020**, 109-144		
158	Quality by design as an emerging concept in the development of pharmaceuticals **2020**, 1-25		
157	Hydrotropy, mixed hydrotropy, and mixed solvency as trending concept for solubilization of lipophilic drugs **2020**, 145-178		2
156	Prodrug design for improving the biopharmaceutical properties of therapeutic drugs **2020**, 179-226		0
155	Emerging role of nanomedicine in the treatment of neuropathic pain. *Journal of Drug Targeting*, **2020**, 28, 11-22	5.4	6
154	Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug 'Etoposide'. *Materials Science and Engineering C*, **2020**, 106, 110275	8.3	25
153	Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. *Acta Biomaterialia*, **2020**, 101, 43-68	10.8	133
152	Graphene-based hybrid nanoparticle of doxorubicin for cancer chemotherapy. *International Journal of Nanomedicine*, **2019**, 14, 7419-7429	7.3	20
151	Dendrimer grafted albumin nanoparticles for the treatment of post cerebral stroke damages: A proof of concept study. *Colloids and Surfaces B: Biointerfaces*, **2019**, 184, 110488	6	5
150	Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. *Materials Science and Engineering C*, **2019**, 98, 1252-1276	8.3	279
149	Scientific Rationale for Designing Controlled Drug Delivery Systems **2019**, 1-28		3
148	Current Developments in Excipient Science **2019**, 29-83		16

147	Fundamentals of Polymers Science Applied in Pharmaceutical Product Development **2019**, 85-112		2
146	Copolymers and Block Copolymers in Drug Delivery and Therapy **2019**, 173-201		6
145	Ligands for Targeted Drug Delivery and Applications **2019**, 307-342		1
144	Transportation and Biointeraction Properties in Nanomaterials Across Biological Systems **2019**, 343-368		4
143	Importance of Physicochemical Characterization of Nanoparticles in Pharmaceutical Product Development **2019**, 369-400		33
142	Bionanotechnology in Pharmaceutical Research **2019**, 449-471		2
141	Design and Evaluation of Ophthalmic Delivery Formulations **2019**, 473-538		7
140	Design and Fabrication of Brain-Targeted Drug Delivery **2019**, 539-593		4
139	Cutaneous and Transdermal Drug Delivery **2019**, 595-650		2
138	Protein/Peptide Drug Delivery Systems: Practical Considerations in Pharmaceutical Product Development **2019**, 651-684		7
137	Clinical Aspects and Regulatory Requirements for Nanomedicines **2019**, 733-752		9
136	Surface Modification of Biomedically Essential Nanoparticles Employing Polymer Coating. *Methods in Molecular Biology*, **2019**, 2000, 191-201	1.4	8
135	Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. *Drug Discovery Today*, **2019**, 24, 2058-2067	8.8	58
134	Engineered Mesenchymal Stem Cells as Nanocarriers for Cancer Therapy and Diagnosis **2019**, 19-56		
133	Guiding Factors and Surface Modification Strategies for Biomaterials in Pharmaceutical Product Development **2019**, 57-87		1
132	Biomaterials for Sustained and Controlled Delivery of Small Drug Molecules **2019**, 89-152		3
131	Approaches to the Development of Implantable Therapeutic Systems **2019**, 191-224		
130	Nanotechnology in Tissue Engineering **2019**, 225-261		

129	Novel Therapeutic Approaches for the Treatment of Leishmaniasis **2019**, 263-300		
128	Biomaterials and Nanoparticles for Hyperthermia Therapy **2019**, 375-413		1
127	Hyaluronic Acid as an Emerging Technology Platform for Silencing RNA Delivery **2019**, 415-458		1
126	Functionalized Carbon Nanotubes for Protein, Peptide, and Gene Delivery **2019**, 613-637		7
125	Fabrication of Mucoadhesive-Dendrimers as Solid Dosage Forms. *Methods in Molecular Biology*, **2019**, 2000, 93-109	1.4	6
124	Molecular modeling approaches for the discovery of adenosine A receptor antagonists: current status and future perspectives. *Drug Discovery Today*, **2019**, 24, 1854-1864	8.8	21
123	Nanogold-core multifunctional dendrimer for pulsatile chemo-, photothermal- and photodynamic-therapy of rheumatoid arthritis. *Journal of Colloid and Interface Science*, **2019**, 544, 61-77	9.3	49
122	Specialized tablets: ancient history to modern developments **2019**, 615-664		2
121	Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment. *Scientific Reports*, **2019**, 9, 16047	4.9	21
120	Regulatory assessment for controlled drug delivery products **2019**, 721-741		1
119	'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin. *International Journal of Pharmaceutics*, **2019**, 555, 77-99	6.5	60
118	Use of Polymers in Controlled Release of Active Agents **2019**, 113-172		11
117	Growing synergy of nanodiamonds in neurodegenerative interventions. *Drug Discovery Today*, **2019** , 24, 584-594	8.8	11
116	Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. *International Journal of Pharmaceutics*, **2018**, 543, 328-344	6.5	24
115	Carbon nanotubes (CNTs) based advanced dermal therapeutics: current trends and future potential. *Nanoscale*, **2018**, 10, 8911-8937	7.7	54
114	Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers. *Journal of Controlled Release*, **2018**, 269, 277-301	11.7	31
113	Molecular dynamics simulation strategies for designing carbon-nanotube-based targeted drug delivery. *Drug Discovery Today*, **2018**, 23, 235-250	8.8	58
112	Applications of Computers in Pharmaceutical Product Formulation **2018**, 665-703		9

111	Basic Concept and Application of Sampling Procedures **2018**, 303-338	
110	Documentation Protocol in Product Development Including Clinical Records **2018**, 403-440	
109	Sterilization of Pharmaceuticals **2018**, 467-519	2
108	Ethics and Legal Protection of Uses of Computer Applications in Pharmaceutical Research **2018**, 757-770	0
107	Correlation Between In Vitro and In Vivo Screens: Special Emphasis on High Throughput Screening and High Throughput Pharmacokinetic Analysis **2018**, 441-466	
106	Package Types for Different Dosage Forms **2018**, 553-590	1
105	Levels of Solid State Properties: Role of Different Levels During Pharmaceutical Product Development **2018**, 1-30	
104	Concepts of Hypothesis Testing and Types of Errors **2018**, 257-280	1
103	Experimental Design and Analysis of Variance **2018**, 281-301	2
102	Guiding Principles for Human and Animal Research During Pharmaceutical Product Development **2018**, 621-664	1
101	Particulate Level Properties and its Implications on Product Performance and Processing **2018**, 155-220	0
100	DrugExcipient Interaction and Incompatibilities **2018**, 363-402	10
99	Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties **2018**, 731-755	22
98	Protein and Tissue Binding: Implication on Pharmacokinetic Parameters **2018**, 371-399	0
97	Four Stages of Pharmaceutical Product Development **2018**, 637-668	2
96	Polymorphism and its Implications in Pharmaceutical Product Development **2018**, 31-65	3
95	Basics of Crystallization Process Applied in Drug Exploration **2018**, 67-103	1
94	Role of Amorphous State in Drug Delivery **2018**, 105-154	1

93	Statistical Techniques in Pharmaceutical Product Development **2018**, 339-362	
92	Package Development of Pharmaceutical Products **2018**, 521-552	0
91	Food and Drug Laws Affecting Pharmaceutical Product Design, Development, and Commercial Manufacturing **2018**, 591-619	
90	Patents and Other Intellectual Property Rights in Drug Delivery **2018**, 705-730	1
89	Preformulation in Drug Research and Pharmaceutical Product Development **2018**, 1-55	3
88	Physicochemical Aspects to Be Considered in Pharmaceutical Product Development **2018**, 57-83	1
87	Role of Physicochemical Parameters on Drug Absorption and Their Implications in Pharmaceutical Product Development **2018**, 85-116	2
86	Physiologic Factors Related to Drug Absorption **2018**, 117-147	1
85	Physicochemical, Pharmaceutical, and Biological Considerations in GIT Absorption of Drugs **2018**, 149-178	4
84	Influence of Drug Properties and Routes of Drug Administration on the Design of Controlled Release System **2018**, 179-223	3
83	Stability and Degradation Studies for Drug and Drug Product **2018**, 225-257	
82	First-Pass Metabolism Considerations in Pharmaceutical Product Development **2018**, 259-286	
81	Dissolution Profile Consideration in Pharmaceutical Product Development **2018**, 287-336	1
80	Drug Disposition Considerations in Pharmaceutical Product **2018**, 337-369	2
79	Preformulation Studies of Drug Substances, Protein, and Peptides: Role in Drug Discovery and Pharmaceutical Product Development **2018**, 401-433	4
78	Role of Salt Selection in Drug Discovery and Development **2018**, 435-472	4
77	Solubility and Solubilization Approaches in Pharmaceutical Product Development **2018**, 513-547	2
76	Rheology and Its Implications on Performance of Liquid Dosage Forms **2018**, 549-597	1

75	Micromeritics in Pharmaceutical Product Development **2018**, 599-635		3
74	Scale-Up Studies in Pharmaceutical Products Development **2018**, 669-700		2
73	Manipulation of Physiological Processes for Pharmaceutical Product Development **2018**, 701-729		4
72	Impact of Pharmaceutical Product Quality on Clinical Efficacy **2018**, 731-771		
71	Formulation Additives Used in Pharmaceutical Products **2018**, 773-831		3
70	Functionalized carbon nanotubes as emerging delivery system for the treatment of cancer. *International Journal of Pharmaceutics*, **2018**, 548, 540-558	6.5	95
69	Carbon nanotubes in the delivery of anticancer herbal drugs. *Nanomedicine*, **2018**, 13, 1187-1220	5.6	24
68	Budding Alliance of Nanotechnology in RNA Interference Therapeutics. *Current Pharmaceutical Design*, **2018**, 24, 2632-2643	3.3	3
67	Nanostructured Hyaluronic Acid-based Materials for the Delivery of siRNA. *Current Pharmaceutical Design*, **2018**, 24, 2678-2691	3.3	8
66	Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications. *Biomedicine and Pharmacotherapy*, **2018**, 104, 496-508	7.5	86
65	Beyond the BloodBrain Barrier: Facing New Challenges and Prospects of Nanotechnology-Mediated Targeted Delivery to the Brain **2018**, 397-437		4
64	The use of nanoscaffolds and dendrimers in tissue engineering. *Drug Discovery Today*, **2017**, 22, 652-664	8.8	90
63	Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?. *Drug Delivery and Translational Research*, **2017**, 7, 179-187	6.2	28
62	Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. *Drug Discovery Today*, **2017**, 22, 665-680	8.8	123
61	Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship. *Therapeutic Delivery*, **2017**, 8, 1003-1018	3.8	42
60	Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. *Nanomedicine*, **2017**, 12, 2653-2675	5.6	47
59	The Warburg effect and glucose-derived cancer theranostics. *Drug Discovery Today*, **2017**, 22, 1637-1653	8.8	83
58	Novel nanosystems for the treatment of ocular inflammation: Current paradigms and future research directions. *Journal of Controlled Release*, **2017**, 268, 19-39	11.7	84

57	Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. *International Journal of Pharmaceutics*, **2017**, 529, 506-522	6.5	79
56	Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. *Regulatory Toxicology and Pharmacology*, **2017**, 91, 179-189	3.4	39
55	Carbon Nanotubes in Targeting and Delivery of Drugs **2017**, 389-426		5
54	Stroke Management: An Emerging Role of Nanotechnology. *Micromachines*, **2017**, 8,	3.3	28
53	Nanotechnology for the Development of Nanomedicine **2017**, 3-61		25
52	Solid Lipid Nanoparticles for Targeting and Delivery of Drugs and Genes **2017**, 256-286		14
51	Biopolymer-based nanocomposites for transdermal drug delivery **2017**, 81-106		8
50	Pharmacokinetic and Pharmacodynamic Features of Nanoemulsion Following Oral, Intravenous, Topical and Nasal Route. *Current Pharmaceutical Design*, **2017**, 23, 2504-2531	3.3	86
49	Surface Engineered Dendrimers in siRNA Delivery and Gene Silencing. *Current Pharmaceutical Design*, **2017**, 23, 2952-2975	3.3	28
48	Recent Advances in Oncological Submissions of Dendrimer. *Current Pharmaceutical Design*, **2017**, 23, 3084-3098	3.3	49
47	Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems. *Pharmaceutical Nanotechnology*, **2017**, 5, 243-249	4	24
46	Microsponge Embedded Tablets for Sustained Delivery of Nifedipine. *Pharmaceutical Nanotechnology*, **2017**, 5, 192-202	4	19
45	Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. *RSC Advances*, **2016**, 6, 89040-89050	3.7	35
44	Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. *Journal of Colloid and Interface Science*, **2016**, 481, 107-16	9.3	112
43	Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. *Regulatory Toxicology and Pharmacology*, **2016**, 82, 20-31	3.4	61
42	Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. *European Journal of Pharmaceutics and Biopharmaceutics*, **2016**, 102, 202-13	5.7	56
41	Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel. *Nanomedicine*, **2016**, 11, 797-816	5.6	27
40	Mucoadhesion: A promising approach in drug delivery system. *Reactive and Functional Polymers*, **2016**, 100, 151-172	4.6	162

39	Dendrimer-mediated approaches for the treatment of brain tumor. *Journal of Biomaterials Science, Polymer Edition*, **2016**, 27, 557-80	3.5	61
38	Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. *Journal of Biomedical Research*, **2016**, 30, 149-161	1.5	3
37	RNAi-combined nano-chemotherapeutics to tackle resistant tumors. *Drug Discovery Today*, **2016**, 21, 1761-1774	8.8	59
36	Theranostic Nanoseeds for Efficacious Internal Radiation Therapy of Unresectable Solid Tumors. *Scientific Reports*, **2016**, 6, 20614	4.9	51
35	Impact of pegylation on biopharmaceutical properties of dendrimers. *Polymer*, **2015**, 59, 67-92	3.9	69
34	Hollow Gold Nanoparticals as Biocompatible Radiosensitizer: An In Vitro Proof of Concept Study. *Journal of Nano Research*, **2015**, 32, 106-112	1	24
33	Glycyrrhizin Conjugated Dendrimer and Multi-Walled Carbon Nanotubes for Liver Specific Delivery of Doxorubicin. *Journal of Nanoscience and Nanotechnology*, **2015**, 15, 1088-100	1.3	48
32	One platform comparison of solubilization potential of dendrimer with some solubilizing agents. *Drug Development and Industrial Pharmacy*, **2015**, 41, 722-7	3.6	35
31	Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. *Pharmaceutical Research*, **2015**, 32, 1438-50	4.5	87
30	Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. *Pharmaceutical Research*, **2015**, 32, 910-28	4.5	56
29	Abstract 3680: Albumin-chitosan hybrid onconase nanocarriers for mesothelioma therapy **2015**,		8
28	Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders. *Current Pharmaceutical Design*, **2015**, 21, 4427-40	3.3	85
27	siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector. *Current Pharmaceutical Design*, **2015**, 21, 4614-36	3.3	53
26	Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases. *Current Pharmaceutical Design*, **2015**, 21, 4465-78	3.3	77
25	Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. *AAPS PharmSciTech*, **2014**, 15, 388-99	3.9	98
24	Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. *Molecular Pharmaceutics*, **2014**, 11, 3671-83	5.6	37
23	Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. *Journal of Controlled Release*, **2014**, 194, 238-56	11.7	257
22	Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. *Nanomedicine*, **2014**, 9, 2291-308	5.6	59

21	Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. *Biomaterials*, **2014**, 35, 5539-48	15.6	105
20	Dendrimers for Enhanced Drug Solubilization **2013**, 373-409		9
19	The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. *Journal of Nanoparticle Research*, **2013**, 15, 1	2.3	60
18	Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer's Disease. *Current Nanoscience*, **2013**, 9, 46-55	1.4	24
17	STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. *BioMed Research International*, **2013**, 2013, 858946	3	52
16	Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design. *BioMed Research International*, **2013**, 2013, 712678	3	45
15	Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. *Journal of Biomedical Research*, **2013**, 27, 394-405	1.5	15
14	Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. *Current Drug Delivery*, **2013**, 10, 477-91	3.2	40
13	Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer Disease. *Current Nanoscience*, **2013**, 9, 46-55	1.4	25
12	Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment. *Saudi Pharmaceutical Journal*, **2012**, 20, 161-70	4.4	172
11	Evaluation of dendrimer safety and efficacy through cell line studies. *Current Drug Targets*, **2011**, 12, 1478-97	3	52
10	Pulmonary toxicity of carbon nanotubes: a systematic report. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2011**, 7, 40-9	6	174
9	Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2011**, 7, 295-304	6	133
8	Micro- and nanocarrier-mediated lung targeting. *Expert Opinion on Drug Delivery*, **2010**, 7, 781-94	8	91
7	Dendrimers as therapeutic agents: a systematic review. *Journal of Pharmacy and Pharmacology*, **2010**, 61, 989-1003	4.8	133
6	PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. *European Journal of Medicinal Chemistry*, **2009**, 44, 1155-66	6.8	76
5	Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. *Molecular Pharmaceutics*, **2009**, 6, 940-50	5.6	88
4	Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. *Journal of Microencapsulation*, **2009**, 26, 287-96	3.4	137

3	Dendrimers in oncology: an expanding horizon. *Chemical Reviews*, **2009**, 109, 49-87	68.1	415
2	Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. *Journal of Drug Targeting*, **2008**, 16, 758-72	5.4	98
1	Pharmaceutical and Biomedical Potential of PEGylated Dendrimers. *Current Pharmaceutical Design*, **2007**, 13, 415-429	3.3	112